Hli.org
the warning states that a woman should only
use Depo-Provera Contraceptive Injection as
1. Pfizer, "Highlights of Prescribing Information" and
a long-term birth control method (for exam-
"Clinical Pharmacology: Mechanism of Action," De-
ple, longer than two years) if other birth control
po-Provera Contraceptive Injection (Depo-Provera CI) Full
Prescribing Information, October 2010, accessed November
methods are inadequate for her."6
Use of Depo-Provera may be associated with
2. American Col ege of Obstetrics and Gynecology (ACOG),
ectopic pregnancy, thrombophlebitis (in-
"Terms Used in Reference to the Fetus," Terminology Bulletin
flammation of blood vessels associated with
(Chicago: ACOG, September 1965).
blood clots), pulmonary embolism (obstruction
3. Upjohn Pharmaceutical Company, "Now Available in the
of the pulmonary artery by a blood clot, air bub-
U.S.: Depo-Provera Contraceptive Injection," Patient Informa-
ble, or other material, which can cause sudden
tion Brochure, December 1992.
death), cerebrovascular disorders, and partial or
4. "Contraceptives: Case for Public Enquiry," Economic and
complete loss of vision in mothers. More than 5
Political Weekly 29 (1994): 825–6.
percent of users suffer headaches, nervousness,
5. Amy Kaler, "A Threat to the Nation and a Threat to the
abdominal pain or discomfort, dizziness or as-
Men: The Banning of Depo-Provera in Zimbabwe, 1981,"
thenia (weakness). One to 5 percent reported
Journal of Southern African Studies 24 (1998): 347-376.
one or more of these ailments: Decreased libi-
6. U.S. Food and Drug Association, "Black Box Warning
do (sexual desire), depression, nausea, insom-
Added Concerning Long-Term Use of Depo-Provera
nia, leukorrhea (abnormal vaginal discharges),
Contraceptive Injection," FDA Talk Paper, November 17,
2004, accessed November 24, 2014, http://web.archive.org/
pelvic and breast pain, rashes, hot flashes, ede-
ma (swelling), vaginitis and acne.7
7. Pfizer, "Adverse Reactions," Depo-Provera Contraceptive
Despite increased HIV risks, promoters
Injection (Depo-Provera CI) Full Prescribing Information,
won't take "No" for an answer: The Bill
October 2010, accessed November 24, 2014, http://www.ac-
and Melinda Gates Foundation has made
Depo-Provera/Sayana Press the centerpiece
8. "About FP2020," Family Planning 2020, accessed Decem-
delivery method of its "Family Planning 2020"
ber 23, 2014,: www.familyplanning2020.org.
campaign, which aims to provide 120 million poor African and Asian women with long-term
9. Renee Hefron, et al., "Use of hormonal contraceptives and
risk of HIV-1 transmission: a prospective cohort study," The
contraceptives like Depo-Provera by the year
Lancet 12 (2012): 19–26.
2020.8 When a Gates Foundation-funded study found in 2011 that Depo-Provera was likely to more than double HIV transmission rates in African women,9 the foundation did not hesi-tate to continue featuring the drug in its imple-
Copyright Human Life International 2015.
mentation of FP2020.
May be reproduced provided that credit is given.
Depo-Provera has three effects, only two of which are contraceptive.
Dangerous for Women, Deadly
Its third effect, the thinning of the endometrium, makes Depo-
for Unborn Children
Provera sometimes work as an abortifacient.
1What is Depo-Provera? The Depo-Prove-
ra injection is a type of hormonal anti-fer-tility drug that works at times as a contra-
lining of the uterus, is thinned, it is rendered hos-
tested on Third World women first. The World
ceptive, but also sometimes as an abortifacient,
tile to implantation. This means that Depo-Prove-
4Depo-Provera is used for population
control. Depo-Provera was approved for
Health Organization (WHO) used Depo-
a drug that causes abortion in some instances.
ra sometimes acts as an abortifacient, since it ends
use in the United States in October 1992. In
Provera on more than 11,000 women in Kenya,
Its active ingredient is depot medroxyproges-
the life of a new human being after conception.
June 1993, however, Canada's Department of Health
Mexico and Thailand, before submitting it to
terone acetate (DMPA), a synthetic form of the
and Welfare prohibited the use of Depo-Provera,
the FDA for approval. Depo-Provera was also
natural hormone progesterone originally devel-
saying that the drug did not meet Canadian safety
tested on Zimbabwean women, many of whom
oped for the treatment of uterine cancer in the
3The debate over effects is not about sci-
ence, but about language: Many women
standards. Since it is controlled by doctors more
were forced to use it afterwards. This widespread
1950s. A woman on this drug receives 150 mil-
opposed to abortion would be shocked
than by women, population controllers consider
coercion led to the banning of Depo-Provera in
ligrams of DMPA via deep intramuscular injec-
to learn that the steroid drugs they take, such
Depo-Provera to be an excellent tool. In fact,
tion every three months, though there are other
as Depo-Provera, can also cause abortions at
the Food and Drug Administration approved
delivery methods under development, including
the earliest stage of pregnancy. In 1963, the U. S.
the drug primarily under pressure from groups
a self-administered version subcutaneous injec-
Department of Health, Education and Welfare
concerned about the "population explosion" in
5Depo-Provera can cause many ad-
verse reactions: Like all steroid drugs
tion version being marketed in Africa as "Sayana
(HEW) defined "abortion" as "all the measures
the Third World.4 Depo-Provera is now available
powerful enough to impair fertility
which impair the viability of the zygote at any
in more than one hundred countries. As with other
effectively, Depo-Provera can cause a host of
time between the instant of fertilization and the
abortifacients that may have posed a danger to
side effects. Upjohn's information pamphlet
Depo-Provera has both contraceptive
completion of labor." The accepted government
Western women, Depo-Provera was extensively
on Depo-Provera lists more than 60
and abortifacient effects: Depo-Provera
and scientific definition of pregnancy said it be-
adverse reactions suffered by women who
has three effects, only two of which are
gan at fertilization, before implantation. However,
use the compound. Women on Depo-
contraceptive. Like most hormonal drugs, it can
in the mid-1960s, in order to make abortifacients
Provera report an average weight gain of 5.4
both prevent ovulation and thicken cervical mu-
acceptable to women and to circumvent laws de-
pounds in the first year and 16.5 pounds over
cus, making it difficult for the sperm to reach the
signed to prohibit abortion, pro-abortion experts
six years. An FDA paper from November 2004
ovum. Both of these effects would prevent con-
changed the beginning of conception from fer-
says that women should not use Depo-Pro-
ception, hence are "contraceptive" effects. The pa-
tilization to implantation.2 Under the new defi-
vera for more than two years: "The black box
tient information insert for Depo-Provera, how-
nition of conception, if a device or drug — such
warning for Depo-Provera highlights that pro-
ever, says that it also "inhibits the secretion of
as Depo-Provera — prevents implantation, then
longed use of the drug may result in significant
gonadotropins which, in turn, prevents follicular
no abortion takes place even though it acts after
loss of bone density, and that the loss is greater
maturation and ovulation and results in endo-
As with other abortifacients that may have posed a danger
the longer the drug is administered. This bone
metrial thinning."1 When the endometrium, the
to Western women, Depo-Provera was extensively tested on
density loss may not be completely revers-
Third World women first.
ible after discontinuation of the drug. Thus
Source: http://www.hli.org/wp-content/uploads/2013/07/Depo-Provera.pdf
doi: 10.1111/jeb.12556 Contrasting reproductive strategies of triploid hybrid malesin vertebrate mating systems *Institute of Evolutionary Biology and Environmental Studies, University of Zurich, Zurich, Switzerland†Department of Zoology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovak Republic ‡Laboratory of Fish Genetics, Institute of Animal Physiology and Genetics, Libechov, Czech Republic
The Effects of Text Exaggeration and Orthographic Similarity on Correct Identification of Drug Names KRAIG L. SCHELL, KYLE KELLEY & CORY HUNSAKER Angelo State University San Angelo, Texas U.S.A. This study tested the effect of text exaggerations (capital letters, color enhancements) of specific segments of drug names and orthographic similarity differences on correct name recognition. One